Copyright
©The Author(s) 2015.
World J Gastroenterol. Mar 7, 2015; 21(9): 2629-2637
Published online Mar 7, 2015. doi: 10.3748/wjg.v21.i9.2629
Published online Mar 7, 2015. doi: 10.3748/wjg.v21.i9.2629
Table 3 Comparison of predictive ability of GATA5, SFRP2, ITGA4 methylation, when used alone or combined, in colorectal cancer and adenomas
| Sensitivity (95%CI) | Specificity (95%CI) | Odds ratio (95%CI) | P value | |
| Adenomas | ||||
| GATA5 | 43.33% (25.46%-62.57%) | 78.72% (64.34%-89.30%) | 2.83 (1.04-7.73) | 0.039 |
| SFRP2 | 40.00% (22.66%-59.40%) | 72.34% (57.36%-84.38%) | 1.74 (0.66-4.60) | 0.259 |
| ITGA4 | 30.00% (14.37%-49.40%) | 80.85% (66.74%-90.85%) | 1.81 (0.62-5.26) | 0.273 |
| GATA5 or SFRP2 | 63.33% (43.86%-80.07%) | 65.96% (50.69%-79.14%) | 3.35 (1.29-8.71) | 0.012 |
| GATA5 or ITGA4 | 60.00% (40.60%-77.34%) | 65.96% (50.69%-79.14%) | 2.91 (1.13-7.50) | 0.025 |
| SFRP2 or ITGA4 | 55.67% (37.43%-74.53%) | 61.70% (46.38%-75.49%) | 1.48 (0.92-2.39) | 0.114 |
| GATA5 or SFRP2 or ITGA4 | 70.00% (50.60%-85.27%) | 55.32% (40.12%-69.83%) | 1.57 (1.06-2.33) | 0.030 |
| GATA5 and SFRP2 | 26.77% (12.28%-45.89%) | 91.49% (79.62%-90.00%) | 3.13 (1.03-9.51) | 0.032 |
| GATA5 and ITGA4 | 10.00% (2.11%-26.53%) | 82.46% (70.09%-91.25%) | 0.41 (0.10-1.64) | 0.231 |
| SFRP2 and ITGA4 | 13.33% (3.76%-30.72%) | 85.11% (71.69%-93.80%) | 0.88 (0.23-3.31) | 1.000 |
| GATA5 and SFRP2 and ITGA4 | 6.67% (0.82%-22.07%) | 93.62% (82.46%-98.66%) | 1.04 (0.19-5.89) | 1.000 |
| Colorectal cancer | ||||
| GATA5 | 61.40% (47.57%-74.00%) | 78.72% (64.34%-89.30%) | 5.89 (2.44-14.18) | < 0.01 |
| SFRP2 | 54.39% (40.66%-67.64%) | 72.34% (57.36%-84.38%) | 3.12 (1.37-7.12) | < 0.01 |
| ITGA4 | 36.84% (24.45%-50.66%) | 80.85% (66.74%-90.85%) | 2.46 (1.00-6.09) | 0.048 |
| GATA5 or SFRP2 | 73.68% (60.34%-84.46%) | 65.96% (50.69%-79.14%) | 5.43 (2.33-12.61) | < 0.01 |
| GATA5 or ITGA4 | 73.68% (60.34%-84.46%) | 65.96% (50.69%-79.14%) | 5.43 (2.33-12.61) | < 0.01 |
| SFRP2 or ITGA4 | 70.18% (56.60%-81.57%) | 61.70% (46.38%-75.49%) | 3.79 (1.67-8.59) | < 0.01 |
| GATA5 or SFRP2 or ITGA4 | 80.70% (68.09%-89.95%) | 55.32% (40.12%-69.83%) | 5.18 (2.16-12.41) | < 0.01 |
| GATA5 and SFRP2 | 42.86% (29.71%-50.00%) | 91.49% (79.62%-90.00%) | 8.06 (2.54-25.5) | < 0.01 |
| GATA5 and ITGA4 | 6.52% (1.37%-17.90%) | 82.46% (70.09%-91.25%) | 0.33 (0.08-1.27) | 0.094 |
| SFRP2 and ITGA4 | 21.05% (11.38%-33.89%) | 85.11% (71.69%-93.80%) | 1.52 (0.55-4.25) | 0.419 |
| GATA5 and SFRP2 and ITGA4 | 15.79% (7.48%-27.87%) | 93.62% (82.46%-98.66%) | 2.75 (0.7-10.82) | 0.217 |
- Citation: Zhang X, Song YF, Lu HN, Wang DP, Zhang XS, Huang SL, Sun BL, Huang ZG. Combined detection of plasma GATA5 and SFRP2 methylation is a valid noninvasive biomarker for colorectal cancer and adenomas. World J Gastroenterol 2015; 21(9): 2629-2637
- URL: https://www.wjgnet.com/1007-9327/full/v21/i9/2629.htm
- DOI: https://dx.doi.org/10.3748/wjg.v21.i9.2629